Barclays PLC Ac Immune Sa Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Ac Immune Sa stock. As of the latest transaction made, Barclays PLC holds 5,290 shares of ACIU stock, worth $17,509. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,290
Previous 7,907
33.1%
Holding current value
$17,509
Previous $16,000
6.25%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ACIU
# of Institutions
43Shares Held
26.8MCall Options Held
94.9KPut Options Held
22.5K-
Bvf Inc San Francisco, CA19.8MShares$65.6 Million3.24% of portfolio
-
Black Rock Inc. New York, NY2.61MShares$8.63 Million0.0% of portfolio
-
Wells Fargo & Company San Francisco, CA1.01MShares$3.34 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny895KShares$2.96 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny770KShares$2.55 Million0.0% of portfolio
About AC Immune SA
- Ticker ACIU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,413,504
- Market Cap $276M
- Description
- AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...